Injection of doubt
31 October 2013
Email
Share
Danish diabetes-treatment giant Novo Nordisk suffered a rare earnings miss, and dropped its double-digit growth target. Generic competition and a cancer scare both hurt. Investors promptly erased 6 percent of Novo’s value. But they are still being generous.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.